Research Documentation & Source Links

Research & regulatory context

FDA source records and external research, properly scoped.

Start with official FDA records for separate named medicines and historical or veterinary products, then browse external research records associated with listed product names or constituents. Neither source set describes, tests, validates, or establishes regulatory approval for an EZpeps product.

FDA regulatory reference

FDA approval history, properly scoped.

Review official FDA records for separate named prescription products, historical records, or veterinary products associated with four listed research-material names. These records provide regulatory context, not product approval.

Important regulatory distinction: The official FDA records below refer only to separate named products, historical records, or veterinary products. They do not apply to any EZpeps product, formulation, strength, lot, package, testing, delivery, or intended use. EZpeps products are research materials only and are not FDA-approved for human or animal use.

Tirzepatide

Distinct named prescription-product records only.

PT-141

FDA source for the distinct named prescription product Vyleesi (bremelanotide injection).

Vyleesi (bremelanotide) FDA approval letter

SS-31 – Elamipretide

FDA source for the distinct named prescription product Forzinity (elamipretide injection).

Gonadorelin

Historical human and current veterinary FDA records for distinct named products only.

General research references

Reference-only research library.

These external compound records expand the library beyond the listed EZpeps catalogue. They are source-navigation entries only: none is an EZpeps product, recommendation, comparison, or product claim.

Important scope: The linked studies and public records concern their own named materials, protocols, populations and, where applicable, distinct regulated products. They do not identify, test, authenticate, characterize, or validate any EZpeps catalogue material. This page provides no medical, dosing, preparation, administration, treatment, safety, efficacy, eligibility, or individual-use guidance.

External compound reference

Semaglutide

Reference-only · not an EZpeps catalogue item

Semaglutide is represented here only through original study and regulatory records. The evidence is specific to each named protocol, population, comparator and endpoint. The FDA record concerns a distinct regulated product and is not evidence about an EZpeps material.

Selected third-party study records

Two primary human study records are provided for source navigation. The summaries below describe design, population, stated endpoints and limitations only; they do not report numerical results or interpret outcomes.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 33567185).

Open the original third-party study record

Evidence tier: Peer-reviewed multicentre randomized controlled trial; primary human study record.
Study design: Double-blind, placebo-controlled, randomized parallel-group trial with a lifestyle intervention and a protocol-defined 68-week treatment period.
Study population: Adults with obesity, or overweight with at least one weight-related coexisting condition, without diabetes, as defined by the study protocol.
Study endpoints: Coprimary endpoints were percentage change in body weight and the proportion achieving the protocol-defined threshold for weight reduction. The study also assessed cardiometabolic measures, physical functioning and adverse events.
Limitations: The selected population excluded diabetes and was defined by protocol eligibility criteria, limiting generalization beyond that context. The intervention was evaluated alongside lifestyle intervention over the study period. The record reports industry funding and does not study or validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 37952131).

Open the original third-party study record

Evidence tier: Peer-reviewed multicentre randomized, double-blind, placebo-controlled event-driven superiority trial; primary human study record.
Study design: Multicentre, double-blind, randomized, placebo-controlled, event-driven superiority trial with time-to-first-event analysis.
Study population: Adults aged 45 years or older with pre-existing cardiovascular disease and overweight or obesity, without diabetes, as defined by the study protocol.
Study endpoints: The primary composite endpoint was time to first cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. Safety was also assessed.
Limitations: The protocol-selected population required established cardiovascular disease and excluded diabetes, so it does not represent every research context. The study was sponsor-funded and does not study or validate EZpeps material.

Study-record limitation: The records are not interchangeable and do not establish claims about every population, formulation, source or material. Sponsor involvement is reported in the original records. Neither study examined or validated an EZpeps material.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine; New England Journal of Medicine Peer-reviewed randomized controlled trial record
Open original source 2
PubMed / U.S. National Library of Medicine; New England Journal of Medicine Peer-reviewed randomized controlled trial record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered interventional study record
Open original source 4
U.S. Food and Drug Administration FDA regulatory record for a distinct approved product

Reference-only research-library entry. This compound is not an EZpeps catalogue product. The records below concern their own study materials, protocols, populations and, where applicable, distinct regulated products; they do not study, validate, authenticate or characterize any EZpeps material. This entry is source navigation only, not a product claim, clinical guidance, dosing or administration information, safety or efficacy advice, or a recommendation.

External compound reference

Tesamorelin

Reference-only · not an EZpeps catalogue item

Tesamorelin is represented through original human research and regulatory records in defined HIV-associated study settings. These records concern the named study intervention or a distinct regulated product, not an EZpeps material.

Selected third-party study records

The selected records are human studies of specific tesamorelin research interventions in defined populations. They should be read as study-specific source records only.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 25038357).

Open the original third-party study record

Evidence tier: Peer-reviewed randomized controlled human trial.
Study design: Double-blind, randomized, placebo-controlled clinical trial conducted at a single centre with a six-month study period.
Study population: Antiretroviral-treated adults living with HIV who had abdominal fat accumulation in the study setting.
Study endpoints: Primary endpoints were changes in visceral adipose tissue and liver fat. Secondary endpoints included glucose and other metabolic measures.
Limitations: This was a single-centre, relatively small, population-specific trial with limited follow-up. The original authors noted the need for further research on clinical importance and longer-term consequences. The study does not validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 20101189).

Open the original third-party study record

Evidence tier: Peer-reviewed randomized placebo-controlled human trial with extension.
Study design: Two-phase blinded randomized placebo-controlled study: a six-month primary phase followed by a protocol-defined extension with treatment reassignment.
Study population: Adults living with HIV who were receiving antiretroviral therapy and had excess abdominal fat in the study context.
Study endpoints: Primary endpoint was visceral adipose tissue. Secondary measures included body image, IGF-I, glucose-related safety measures and body-composition measures.
Limitations: The population was restricted to a defined HIV-associated research setting; the extension and treatment switching require interpretation within the protocol. The record does not validate EZpeps material or establish findings outside the studied intervention and population.

Study-record limitation: These studies are limited by defined HIV-associated populations, eligibility criteria, follow-up periods, endpoints and protocol designs. They do not validate EZpeps material, establish results for other populations or formulations, or substitute for regulatory or clinical evaluation.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine Peer-reviewed randomized clinical trial record
Open original source 2
PubMed / U.S. National Library of Medicine Peer-reviewed randomized clinical trial record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered interventional study record
Open original source 4
U.S. Food and Drug Administration FDA regulatory record for a distinct approved product

External compound reference

Teduglutide

Reference-only · not an EZpeps catalogue item

Teduglutide is represented through original study and regulatory records in short-bowel-syndrome-associated intestinal-failure research. The sources concern named study interventions or a distinct approved product, not an EZpeps material.

Selected third-party study records

One adult randomized study record and one pediatric phase III study record are provided. The FDA record documents regulatory context for a distinct product only.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 21317170).

Open the original third-party study record

Evidence tier: Peer-reviewed primary human randomized controlled trial.
Study design: Twenty-four-week multicentre randomized placebo-controlled trial with two study-intervention groups and a placebo group.
Study population: Adults with short bowel syndrome and intestinal failure who required parenteral nutrition or intravenous fluid support.
Study endpoints: The primary endpoint was a protocol-defined graded response score based on parenteral-support reduction and persistence. Other measures included parenteral volume, intestinal fluid absorption, mucosal measures, plasma citrulline and lean body mass.
Limitations: Short follow-up and a relatively small randomized sample constrain precision and longer-term inference. The primary outcome was a composite protocol-specific construct. The record reports sponsor relationships and does not study or validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 31495952).

Open the original third-party study record

Evidence tier: Peer-reviewed primary pediatric phase III study.
Study design: Twenty-four-week study with two randomized, double-blind study-intervention groups and a nonblinded standard-of-care arm.
Study population: Pediatric participants with short-bowel-syndrome-associated intestinal failure receiving parenteral support.
Study endpoints: The primary endpoint was the protocol-defined reduction in parenteral support at week 24. Supporting measures included parenteral-support volume, calories, infusion timing, enteral nutrition, plasma citrulline, growth measures and adverse events.
Limitations: The follow-up was limited, the pediatric cohort was small and the standard-of-care comparator was nonblinded. Results remain specific to the protocol and do not establish safety, quality or validation of EZpeps material.

Study-record limitation: The records are study-specific, rather than a unified assessment of all teduglutide materials or uses. Differences in formulation, population, comparator, follow-up, eligibility and endpoint definitions limit comparison and generalization. No EZpeps material was studied.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine; Gut Peer-reviewed randomized controlled trial record
Open original source 2
PubMed / U.S. National Library of Medicine; JPEN Peer-reviewed primary human study record
Open original source 3
U.S. Food and Drug Administration FDA regulatory record for the distinct approved product GATTEX

External compound reference

Cetrorelix

Reference-only · not an EZpeps catalogue item

Cetrorelix is represented through protocol-specific assisted-reproduction research records and a historical FDA label for the distinct Cetrotide product. Neither type of record identifies, studies or validates an EZpeps material.

Selected third-party study records

The selected records are primary human studies. Their design, population and endpoints are described as presented in the individual records; no numerical results or benefit interpretations are reported.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 16009165).

Open the original third-party study record

Evidence tier: Peer-reviewed human clinical trial; PubMed-indexed phase IV comparative study.
Study design: Prospective, open-label, randomized comparative study across multiple assisted-reproduction centres within a programmed flexible ovarian-stimulation protocol.
Study population: Women undergoing assisted reproductive technology in the study’s cycle-programmed ovarian-stimulation setting.
Study endpoints: The stated primary outcome was the proportion without a premature luteinizing-hormone surge on the hCG-administration day. IVF/ICSI, embryo-transfer and safety measures were also assessed.
Limitations: Open-label design and a specific assisted-reproduction protocol limit transferability. The comparison, preparation and study setting are specific to the record. The study does not validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 20810107).

Open the original third-party study record

Evidence tier: Peer-reviewed human randomized controlled trial.
Study design: Randomized controlled comparison of two gonadotropin ovulation-induction and intrauterine-insemination protocols, with or without the study intervention.
Study population: Women undergoing protocol-defined gonadotropin ovulation induction with intrauterine insemination for infertility.
Study endpoints: Stated outcomes included premature luteinization, clinical pregnancy and cycle cancellation.
Limitations: The study was a short, setting-specific infertility trial and the PubMed record provides limited details beyond the abstract. It does not establish results for other settings, formulations or materials and does not validate EZpeps material.

Study-record limitation: Evidence is protocol- and preparation-specific. The studies concern selected assisted-reproduction populations and outcomes, so they do not establish findings for other populations, formulations or materials. The historical FDA label is regulatory context for a distinct product only.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine Peer-reviewed human clinical-trial record
Open original source 2
PubMed / U.S. National Library of Medicine Peer-reviewed human randomized-trial record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered interventional study record
Open original source 4
U.S. Food and Drug Administration Historical FDA regulatory label for a distinct approved product

External compound reference

Larazotide

Reference-only · not an EZpeps catalogue item

Larazotide, also called larazotide acetate or AT-1001 in study records, is represented through original human research records in celiac-disease settings. The FDA source is an ingredient-identity record, not an approval or labeling record. No EZpeps material was used or validated in these studies.

Selected third-party study records

The selected records are human studies of specific larazotide acetate research formulations and protocols. They are study-specific evidence only and do not support extrapolation to other preparations or uses.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 23163616).

Open the original third-party study record

Evidence tier: Peer-reviewed primary human randomized controlled trial.
Study design: Exploratory, double-blind, randomized, placebo-controlled, parallel-group human study following a gluten-free-diet run-in, a protocol-defined gluten challenge and follow-up.
Study population: Adults with celiac disease who were maintaining a gluten-free diet before and during the study.
Study endpoints: Stated outcomes included an experimental intestinal-permeability biomarker, gastrointestinal symptom scores, anti-tissue-transglutaminase antibody levels and tolerability or adverse-event assessments.
Limitations: The original authors characterized the study as exploratory. The biomarker was experimental and the gluten-challenge setting, selected adult population and protocol-specific outcomes limit generalization. The record does not validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 25683116).

Open the original third-party study record

Evidence tier: Peer-reviewed primary human multicentre randomized controlled trial.
Study design: Multicentre, randomized, double-blind, placebo-controlled study with a placebo run-in, a protocol-defined blinded period and a placebo run-out period.
Study population: Adults with established celiac disease, persistent gluten-related symptoms and at least 12 months of a gluten-free diet, subject to the study’s eligibility criteria.
Study endpoints: The primary endpoint was a protocol-defined gastrointestinal symptom-rating score. Secondary and exploratory measures included patient-reported domains, safety assessments and selected serologic measures.
Limitations: The selected adult population had multiple eligibility and medication exclusions and remained on an existing diet. Symptom-based endpoints and the study design do not validate other formulations or EZpeps material and do not establish a general product or clinical claim.

Study-record limitation: The selected studies enrolled defined adult celiac-disease populations and used protocol-specific comparators, eligibility criteria, follow-up and outcome measures. Registry listing does not mean the U.S. government has reviewed or approved the science of every listed study. None of these records validate EZpeps material.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine Peer-reviewed primary human randomized controlled trial record
Open original source 2
PubMed Central / U.S. National Library of Medicine; Gastroenterology Peer-reviewed primary human randomized controlled trial record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered interventional study record
Open original source 4
U.S. Food and Drug Administration GSRS/UNII Official substance-identity record; not an approval record

External compound reference

Kisspeptin-54

Reference-only · not an EZpeps catalogue item

Kisspeptin-54 is represented through experimental human endocrinology and reproductive-research records. The sources describe their own investigational materials and procedures; they do not establish properties, quality, identity, safety, efficacy or regulatory status for any EZpeps material.

Selected third-party study records

Two selected peer-reviewed human records are provided. Each describes a particular investigational material and study population, not an EZpeps material.

Study record 1 — design, population and limitations

Peer-reviewed study record (PMID: 16174713).

Open the original third-party study record

Evidence tier: Peer-reviewed randomized controlled human study.
Study design: Double-blind, placebo-controlled crossover study in a hospital research setting; each participant underwent a study-specific exposure and saline-control exposure in randomized order.
Study population: Adult male volunteers recruited for the study.
Study endpoints: Plasma luteinizing hormone, follicle-stimulating hormone and testosterone concentrations; the record also reports pharmacokinetic measures.
Limitations: The study used a small volunteer sample, short observation period and male research population. It assessed hormone-response measures rather than patient-centred clinical outcomes and does not validate EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed study record (PMID: 25036713).

Open the original third-party study record

Evidence tier: Peer-reviewed clinical trial; PubMed/PMC full text.
Study design: Clinical IVF study using a single study-specific exposure after controlled ovarian stimulation and gonadotropin-releasing-hormone-antagonist treatment; retrieval and laboratory assessment followed the trial protocol.
Study population: Women undergoing IVF who met the study’s age, menstrual-cycle, ovarian-reserve, body-mass-index and other eligibility criteria.
Study endpoints: Primary endpoints were the number and percentage of retrieved eggs classified as mature. Secondary measures included reproductive hormones, fertilisation, embryo measures and pregnancy assessments.
Limitations: This was a single-centre, protocol-specific IVF investigation in a selected population with limited sample size. Its endpoints cannot be generalized to other populations or materials, and it does not validate EZpeps material or establish routine clinical use.

Study-record limitation: The records are small, study-specific human investigations with selected populations and specialised research settings. Their designs do not establish general clinical effectiveness, long-term outcomes or conclusions about commercial materials. Registry information is not evidence that an EZpeps product was used or validated.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine Peer-reviewed primary human study record
Open original source 2
PubMed Central / U.S. National Library of Medicine; Journal of Clinical Investigation Peer-reviewed primary human clinical-study record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered human study record

External compound reference

AOD-9604

Reference-only · not an EZpeps catalogue item

AOD-9604 is represented through peer-reviewed preclinical records and FDA regulatory information. The selected laboratory and animal-model records are not human evidence. The FDA page concerns a compounding context and is not an approval, product-quality assessment or clinical-use authorization.

Selected third-party study records

No appropriate human study record is included in this entry. The selected records are peer-reviewed animal and cell studies, so their findings must not be generalized to people, products or EZpeps material.

Study record 1 — design, population and limitations

Peer-reviewed preclinical study record (PMID: 11146367).

Open the original third-party study record

Evidence tier: Peer-reviewed preclinical primary study.
Study design: Controlled animal experiment comparing the study material with a control in obese Zucker rats; metabolic assessments included body-weight change, adipose lipolytic activity and glucose or insulin-sensitivity testing.
Study population: Obese Zucker rats; not humans.
Study endpoints: Body-weight gain, adipose-tissue lipolytic activity and insulin sensitivity assessed with euglycemic-clamp methods.
Limitations: Animal-model findings cannot establish human effects or safety. The record does not provide clinical outcome evidence, long-term safety characterization or validation of any commercial or EZpeps material.

Study record 2 — design, population and limitations

Peer-reviewed preclinical study record (PMID: 11673763).

Open the original third-party study record

Evidence tier: Peer-reviewed preclinical primary study.
Study design: Comparative controlled experiment in obese and lean mice, with a fragment group, a growth-hormone comparator and saline control; it also included in-vitro receptor-binding and cell-proliferation assays.
Study population: Obese ob/ob mice, lean C57BL/6J mice and cultured engineered cells; not humans.
Study endpoints: Body weight, caloric intake, energy expenditure, fat and glucose oxidation, selected plasma measures, receptor binding and cell proliferation.
Limitations: The work is preclinical and uses specific mouse and engineered-cell models. It cannot establish human clinical outcomes or product-specific safety and does not study or validate EZpeps material.

Study-record limitation: Preclinical records do not establish human safety, efficacy, clinical usefulness, regulatory approval or product equivalence. FDA regulatory information applies to its nominated-substance and compounding context; it does not authorize clinical use or validate any EZpeps product.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine Peer-reviewed preclinical primary study record
Open original source 2
PubMed / U.S. National Library of Medicine Peer-reviewed preclinical primary study record
Open original source 3
U.S. Food and Drug Administration Official regulatory information; not an approval record

External compound reference

Humanin

Reference-only · not an EZpeps catalogue item

Humanin is an experimental research subject represented through a peer-reviewed translational record and an observational registry record. These materials do not identify, study or validate any EZpeps material.

Selected third-party study records

The selected peer-reviewed record is a translational study containing animal experiments and observational human measurements. The registry record is an observational biomarker source; it is not a study of administered Humanin.

Study record 1 — design, population and limitations

Peer-reviewed translational study record (PMID: 32575074).

Open the original third-party study record

Evidence tier: Peer-reviewed translational primary research; animal intervention plus observational human measurements.
Study design: Mixed experimental design including expression and transgenic experiments in C. elegans and mice, mouse treatment experiments using a Humanin analogue and observational measurements of Humanin in human and other-species samples.
Study population: C. elegans, mice and observational human samples, including centenarian-family and disease-associated samples. The human component was not a clinical intervention cohort.
Study endpoints: Animal endpoints included lifespan, healthspan-related metabolic and inflammatory measures and responses to toxic insult. Human observational endpoints included measured Humanin levels and associations with age, mitochondrial measures, longevity-related status or disease context.
Limitations: The study does not test administered Humanin in humans. Animal findings may not translate to people, the mouse intervention used an analogue and human observations are nonrandomized and associative. No EZpeps material was studied or validated.

Study-record limitation: The translational paper does not test administered Humanin in humans. Animal findings may not translate to people, and the human measurements are observational and associative. The registry source is observational and does not constitute clinical intervention evidence. None of these records validate EZpeps material.

Original public sources

Open original source 1
PubMed / U.S. National Library of Medicine; Aging Peer-reviewed translational primary research record
Open original source 2
PubMed / U.S. National Library of Medicine Peer-reviewed preclinical primary research record
Open original source 3
ClinicalTrials.gov / U.S. National Library of Medicine Registered observational study record

Research Documentation

External research records, organized by listed product.

Each entry is a source index for external publications or study records associated with the name or named constituents in the listed product. The source links are not product claims and do not establish an intended use, quality, identity, safety, suitability, outcome, or regulatory status for any EZpeps product.

Research-material limitation: This page is not medical information and does not provide dosing, preparation, administration, treatment, eligibility, efficacy, safety, or individual-use guidance. The linked sources concern their own study materials and protocols, not EZpeps products.

Listed product

LL-37

The links below index external research records associated with the compound name or constituent names in this listing. They are provided for source navigation only and do not describe, test, or validate this EZpeps product.

Selected third-party study records

Evidence tier: Limited human evidence from small, formulation-specific randomized wound studies in venous leg-ulcer and diabetic-foot-ulcer populations. The studies do not establish evidence for systemic use or for an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 34687253).

Open the original third-party study record

Evidence tier: Limited human evidence; phase IIb randomized clinical trial.
Study design: Multicenter, prospective, double-blind, randomized, placebo-controlled, three-arm phase IIb clinical trial evaluating a specified LL-37 study formulation in patients receiving compression therapy.
Study population: 148 adults with hard-to-heal venous leg ulcers; reported mean age was 67.6 years, median ulcer duration 20.3 months, and mean wound area at randomization 11.6 cm².
Study endpoints: Stated study outcomes included ulcer-healing efficacy measures and safety/tolerability measures, including healing-related parameters for the target ulcer.
Limitations: Evidence is limited to the specified study formulation, venous-leg-ulcer setting, and selected study population. The publication reports a prespecified full-cohort comparison and exploratory post hoc subgroup analyses; subgroup findings are not confirmatory. The study does not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 2 — design, population and limitations

PubMed study record (PMID: 37480520).

Open the original third-party study record

Evidence tier: Limited human evidence; randomized double-blind controlled clinical trial.
Study design: Randomized, double-blind, placebo-controlled clinical trial evaluating a specified LL-37 cream formulation in a diabetic-foot-ulcer wound-care setting; registered as ClinicalTrials.gov NCT04098562.
Study population: People with diabetic foot ulcers described in the publication as having mild infection; the study was conducted in Jakarta, Indonesia.
Study endpoints: Stated study outcome measures included wound-healing rate, granulation index, wound-fluid IL-1α and TNF-α levels, and aerobic bacterial colonization.
Limitations: Evidence is limited to a specified cream formulation, diabetic-foot-ulcer population, mild-infection setting, and study context; it does not establish broader clinical applicability. Biomarker and colonization measures are study endpoints, not evidence of benefit for other conditions. The study does not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: These records concern specific clinical study materials and wound-care contexts, not generic LL-37 or an EZpeps research material. They do not establish identity, quality, equivalence, safety, suitability, or use of the EZpeps material. Clinical-trial registration alone does not establish an outcome; a registry without posted results is not evidence of an outcome.

Additional third-party sources

Open research source 1
MDPI, Antibiotics (indexed in PubMed/PMC) Peer-reviewed narrative review; PubMed Central full text
Open research source 2
Wiley, BioFactors (PubMed record maintained by the U.S. National Library of Medicine) PubMed-indexed peer-reviewed review
Open research source 3
ClinicalTrials.gov, U.S. National Library of Medicine ClinicalTrials.gov observational study record
Open research source 4
ClinicalTrials.gov, U.S. National Library of Medicine ClinicalTrials.gov observational study record

Listed product

ARA 290

Selected third-party study records

Evidence tier: limited human evidence from small, condition-specific exploratory studies, plus peer-reviewed preclinical animal evidence. The animal study is not human clinical evidence, and none of these records establish evidence for an EZpeps research material.

Study record 1 — design, population and limitations

Peer-reviewed full-text study record (PubMed Central).

Open the original third-party study record

Evidence tier: Peer-reviewed randomized human pilot study; limited and exploratory evidence.
Study design: Single-site, randomized, double-blind, placebo-controlled exploratory pilot study.
Study population: Adults with confirmed sarcoidosis and symptoms consistent with small-fiber neuropathy and clinically significant spontaneous pain; 22 participants completed the study analysis (12 ARA 290 and 10 placebo).
Study endpoints: Prespecified study endpoints included change in pain intensity, Small Fiber Neuropathy Screening List score, SF-36 quality-of-life measures, Inventory of Depressive Symptomatology score, and Fatigue Assessment Scale score.
Limitations: Small single-site pilot with short study duration, questionnaire-based outcomes, participant withdrawals and replacement participants; the population was restricted to sarcoidosis-associated neuropathic symptoms, limiting generalizability. This study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 2 — design, population and limitations

Peer-reviewed full-text study record (PubMed Central).

Open the original third-party study record

Evidence tier: Peer-reviewed phase 2 human pilot study; limited, open-label, exploratory evidence.
Study design: Prospective, interventional, investigator-led, open-label, exploratory phase 2 pilot study.
Study population: Adults with type 1 or type 2 diabetes and center-involving diabetic macular edema meeting the study's retinal-thickness criterion, with no previous treatment for diabetic macular edema; 9 participants were recruited and 8 completed the study.
Study endpoints: The primary outcome measure was mean change from baseline to week 12 in best-corrected visual acuity. Secondary outcome measures included central retinal thickness, central retinal sensitivity, retinal perfusion, tear production, patient-reported outcomes, specified visual-acuity letter-gain thresholds, cibinetide antibodies, and adverse events; exploratory measures included metabolic status, renal function, and serum proteins.
Limitations: Very small, single-center, open-label, non-comparative pilot with short follow-up and participant attrition; findings are specific to the selected diabetic-macular-edema population and exploratory outcome framework. This study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 3 — design, population and limitations

Swartjes et al., Anesthesiology (2011), PubMed PMID: 21873879.

Open the original third-party study record

Evidence tier: Preclinical evidence only; peer-reviewed experimental animal study.
Study design: Controlled post–peripheral-nerve-injury animal experiment comparing a specified ARA290 research protocol with vehicle. It included an early-treatment rat group and allodynia assessments in wild-type and β-common-receptor knockout mice.
Study population: Sprague-Dawley rats and mice in an experimental spared-nerve-injury model; the abstract reports eight animals per group.
Study endpoints: Tactile and cold allodynia measures, including follow-up in rats to 15 weeks, with comparative allodynia findings in wild-type and β-common-receptor knockout mice.
Limitations: Animal-model, peripheral-nerve-injury, and protocol-specific research only. It is not human clinical evidence and does not establish identity, quality, equivalence, safety, suitability, outcome, or use of an EZpeps research material.

Study-record limitation: These studies are not studies of an EZpeps product and do not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material. The human records are small and condition-specific; the added animal record uses an experimental peripheral-nerve-injury model and cannot be generalized to people or an unstudied formulation. Neither record should be interpreted as a recommendation or as evidence for an EZpeps research material.

Additional third-party sources

Open research source 1
Molecular Medicine / PubMed Central Peer-reviewed primary randomized pilot study; PubMed-indexed
Open research source 2
Molecular Medicine / PubMed, National Library of Medicine Peer-reviewed primary Phase II clinical trial; PubMed-indexed
Open research source 3
Expert Opinion on Investigational Drugs / PubMed, National Library of Medicine Peer-reviewed review; PubMed-indexed
Open research source 4
ClinicalTrials.gov, National Library of Medicine / U.S. National Institutes of Health Official ClinicalTrials.gov study record
Open research source 5
Pain Reports / PubMed Central Peer-reviewed narrative review of preclinical and limited human ARA290 research; PubMed-indexed
Open research source 6
Anesthesiology / PubMed, U.S. National Library of Medicine Peer-reviewed primary preclinical animal study; PubMed-indexed

Listed product

SEMAX + SELANK combo

The links below index external research records for named constituent(s) in this blend. Unless a source explicitly states otherwise, they concern constituents separately and do not describe, test, or validate this exact EZpeps blend.

Selected third-party study records

Limited human component evidence; no direct clinical study of the Semax-plus-Selank blend was identified. The selected peer-reviewed study evaluated Semax and Selank as separate study groups with placebo comparison, so it is not evidence for the combined blend.

Study record 1 — design, population and limitations

PubMed study record (PMID: 32342318).

Open the original third-party study record

Evidence tier: Limited human component evidence; no direct evidence for the Semax-plus-Selank blend.
Study design: Peer-reviewed controlled human neuroimaging study with separate Semax and Selank groups and placebo comparison; repeated resting-state functional MRI assessments.
Study population: 52 healthy adult participants.
Study endpoints: Whole-brain resting-state functional connectivity for predefined regions of interest, including the amygdala and dorsolateral prefrontal cortex, assessed with resting-state fMRI.
Limitations: The study did not evaluate a combined Semax-plus-Selank formulation, used a small healthy-participant sample, and assessed neuroimaging connectivity rather than clinical outcomes. Its findings cannot establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: No authoritative direct study of the Semax-plus-Selank blend was identified in the verified sources reviewed. Component evidence must not be generalized to the blend. The cited paper is research evidence about its specific study materials and population, not evidence of identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
National Library of Medicine (PubMed); journal: Zh Nevrol Psikhiatr Im S S Korsakova PubMed-indexed clinical trial
Open research source 2
National Library of Medicine (PubMed); journal: Zh Nevrol Psikhiatr Im S S Korsakova PubMed-indexed randomized controlled trial
Open research source 3
National Library of Medicine (PubMed); journal: Bulletin of Experimental Biology and Medicine PubMed-indexed human neuroimaging study
Open research source 4
National Library of Medicine (PubMed); journal: Doklady Biological Sciences PubMed-indexed human neuroimaging study

Listed product

SELANK

Selected third-party study records

Evidence tier: limited human evidence from one small randomized comparative clinical study. The study evaluated Selank in a defined clinical population; it does not establish broad clinical evidence.

Study record 1 — design, population and limitations

PubMed study record (PMID: 18454096).

Open the original third-party study record

Evidence tier: Limited human evidence; one small randomized comparative clinical study.
Study design: Randomized controlled comparative study of Selank versus medazepam, with clinical and biological assessments.
Study population: 62 patients with generalized anxiety disorder and neurasthenia; 30 assigned to Selank and 32 to medazepam. The PubMed record describes adult, adolescent, male, and female participants in its indexing, but gives no further demographic breakdown in the abstract.
Study endpoints: Psychometric assessments using the Hamilton, Zung, and Clinical Global Impression (CGI) scales; blood-serum enkephalin activity was also measured.
Limitations: Small sample; older 2008 publication; article is in Russian; the PubMed abstract provides limited detail on allocation, masking, follow-up, and prespecified analysis. The study is specific to its population, comparator, and study material and does not establish identity, quality, equivalence, safety, suitability, or use of any EZpeps research material.

Study-record limitation: This index entry summarizes a single PubMed record and should not be read as a recommendation or as evidence that an EZpeps research material is the same as the studied material. The study material is not evidence of identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
PubMed / U.S. National Library of Medicine (record for Zh Nevrol Psikhiatr Im S S Korsakova, 2008) PubMed-indexed randomized controlled trial / comparative clinical study
Open research source 2
PubMed / U.S. National Library of Medicine (record for Zh Nevrol Psikhiatr Im S S Korsakova, 2014) PubMed-indexed clinical trial / comparative study
Open research source 3
PubMed / Bentham Science Publishers Ltd. (Protein & Peptide Letters, 2018) PubMed-indexed peer-reviewed review and molecular research article
Open research source 4
PubMed Central / Frontiers Media (Frontiers in Pharmacology, 2016) PubMed-indexed peer-reviewed preclinical animal study

Listed product

SEMAX

Selected third-party study records

Semax is indexed here as an EZpeps research material. The cited publication is evidence only about the study material and study conditions reported by the investigators; it does not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 30225715).

Open the original third-party study record

Evidence tier: Limited human primary evidence: controlled neuroimaging study in healthy volunteers.
Study design: Controlled, placebo-comparator human study using repeated resting-state functional MRI assessments; 24 healthy volunteers were studied in two groups.
Study population: 24 healthy adults (11 men and 13 women; mean age 43.9 ± 9.5 years). The population was healthy volunteers rather than patients with a clinical disorder.
Study endpoints: Prespecified/stated imaging outcomes were resting-state default-mode-network topography and the volume of its rostral medial-frontal subcomponent, assessed by resting-state functional MRI.
Limitations: Small sample and short observation window; imaging outcomes were used rather than clinical endpoints, and the healthy-volunteer population limits clinical generalizability. This study does not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: This record is a concise index of one independently published Semax study, not a product validation. The study material and any EZpeps research material should not be presumed identical or equivalent; the publication does not establish quality, safety, suitability, or use of the EZpeps material.

Additional third-party sources

Open research source 1
PubMed (U.S. National Library of Medicine); article in Bulletin of Experimental Biology and Medicine PubMed-indexed human research study
Open research source 2
PubMed (U.S. National Library of Medicine); article in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova PubMed-indexed clinical trial publication
Open research source 3
PubMed (U.S. National Library of Medicine); article in Doklady Biological Sciences PubMed-indexed human resting-state fMRI study
Open research source 4
PubMed (U.S. National Library of Medicine); article in Neurochemical Research PubMed-indexed preclinical animal research

Listed product

DSIP

Selected third-party study records

Limited, older human clinical evidence is available for DSIP, chiefly small controlled sleep studies in people with chronic insomnia. The cited studies are evidence about their specific research protocols and materials only; they are not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 1299794).

Open the original third-party study record

Evidence tier: Limited human evidence; small randomized controlled clinical trial.
Study design: Double-blind, matched-pairs, parallel-groups clinical trial conducted over five consecutive laboratory nights, with polysomnographic and subjective assessments.
Study population: 16 patients with chronic insomnia; PubMed indexing identifies adult and older participants and both women and men.
Study endpoints: Prespecified or stated measures included sleep structure, objective sleep quality assessed by polysomnography, subjective sleep quality, and subjective tiredness.
Limitations: Small sample, short laboratory observation period, and older single-study evidence limit precision and generalizability; the study did not establish long-term outcomes or conclusions about an EZpeps research material.

Study record 2 — design, population and limitations

PubMed study record (PMID: 3622582).

Open the original third-party study record

Evidence tier: Limited human evidence; small controlled clinical trial.
Study design: Placebo-controlled, double-blind clinical trial with repeated sleep-wake assessments and laboratory polysomnography.
Study population: 14 middle-aged people with severe chronic insomnia.
Study endpoints: Stated study outcome measures included polysomnographic sleep measures, daytime psychological state, and daytime mental-performance testing.
Limitations: Small sample and older, single-center-style study context limit generalizability; the abstract provides limited methodological detail, and the study does not establish long-term outcomes or conclusions about an EZpeps research material.

Study-record limitation: These records document small, older studies of specific study materials and populations, not a validated evidence base for an EZpeps product. They do not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material. Registry status was not used as evidence here; in general, a registry without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
U.S. National Library of Medicine (PubMed); Journal of Neurochemistry PubMed-indexed review
Open research source 2
U.S. National Library of Medicine (PubMed); Neuroscience & Biobehavioral Reviews PubMed-indexed review
Open research source 3
U.S. National Library of Medicine (PubMed); International Journal of Clinical Pharmacology, Therapy and Toxicology PubMed-indexed controlled clinical trial
Open research source 4
U.S. National Library of Medicine (PubMed); Neuropsychobiology (S. Karger AG) PubMed-indexed randomized controlled clinical trial

Listed product

CAGRILINTIDE

Selected third-party study records

Evidence tier: Robust human evidence from a peer-reviewed, randomized phase 2 trial of investigational cagrilintide monotherapy in adults with overweight or obesity. The evidence is specific to the studied trial product, protocol, and population; it does not establish that an EZpeps research material has the same identity, quality, equivalence, safety, suitability, or use.

Study record 1 — design, population and limitations

PubMed study record (PMID: 34798060).

Open the original third-party study record

Evidence tier: Peer-reviewed primary human evidence; randomized phase 2 clinical trial of investigational cagrilintide monotherapy.
Study design: Multicentre, randomized, double-blind, placebo-controlled and active-controlled phase 2 clinical trial; 906 adults were randomized across cagrilintide, liraglutide, and placebo groups.
Study population: Adults aged 18 years or older without diabetes who had obesity, or overweight with hypertension or dyslipidaemia, recruited at 57 sites in 10 countries.
Study endpoints: Prespecified primary endpoint: percentage change in bodyweight from baseline to week 26 under trial-product and treatment-policy estimands. The protocol also assessed safety and tolerability.
Limitations: Investigational, trial-product-specific evidence from a phase 2 study in adults without diabetes; the study population and protocol limit generalizability. The trial was funded by Novo Nordisk, and several authors were Novo Nordisk employees or shareholders. It does not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: This record summarizes study design and named outcome measures, not study results or recommendations. A ClinicalTrials.gov registry record without posted results establishes that a study was registered, not an outcome. Cagrilintide study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
PubMed / National Library of Medicine (record for The Lancet) PubMed-indexed primary clinical trial
Open research source 2
The Lancet / Elsevier Peer-reviewed journal article
Open research source 3
PubMed / National Library of Medicine (record for Cardiology in Review) PubMed-indexed peer-reviewed review
Open research source 4
ClinicalTrials.gov / U.S. National Library of Medicine Official clinical-trial registry record

Listed product

GONADORELIN

Selected third-party study records

Human evidence for gonadorelin (GnRH) is indication- and study-context-specific, with much of the literature historical and tied to particular clinical protocols or delivery systems. These records do not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 3079597).

Open the original third-party study record

Evidence tier: Primary human clinical evidence; older, controlled comparative clinical trial.
Study design: Controlled clinical trial and comparative study evaluating pulsatile GnRH in induced cycles, with comparison to reference ovulatory cycles.
Study population: Eighteen women with well-characterized hypothalamic amenorrhea; 30 induced cycles were evaluated, alongside 62 reference ovulatory cycles from women without the condition.
Study endpoints: Study measures included ovulation, follicular development, peak serum estradiol, integrated luteal-phase progesterone, and pregnancy occurrence.
Limitations: Small, older study in a narrowly defined reproductive-endocrine population; findings are specific to the studied protocol and clinical context and should not be generalized to an EZpeps research material or other formulations.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT07152730).

Open the original third-party study record

Evidence tier: Registered Phase 1 human study; withdrawn, with no posted results.
Study design: Open-label, nonrandomized, parallel-assignment interventional pharmacokinetic study in healthy volunteers.
Study population: Healthy female volunteers aged 18 to 40 years with regular menstrual cycles; actual enrollment was zero.
Study endpoints: Prespecified pharmacokinetic exposure and time-course measures.
Limitations: The registry lists the study as withdrawn with zero enrollment and no posted results; registration and stated outcome measures do not establish any outcome. The record concerns a named investigational product and delivery system, not an EZpeps research material.

Study-record limitation: These records are evidence about the specific studied GnRH/gonadorelin contexts only. A study record or publication is not evidence of identity, quality, equivalence, safety, suitability, or use of an EZpeps research material; the withdrawn registry without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
PubMed (U.S. National Library of Medicine); journal record: American Journal of Men's Health PubMed-indexed primary human clinical study
Open research source 2
PubMed (U.S. National Library of Medicine); journal record: Journal of Clinical Endocrinology & Metabolism PubMed-indexed primary human clinical trial
Open research source 3
ClinicalTrials.gov (U.S. National Library of Medicine) Official clinical-trial registry record

Listed product

PT-141

Selected third-party study records

Peer-reviewed phase 3 human evidence exists for bremelanotide in a defined population: premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). The evidence is population- and study-product-specific and should not be generalized to an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 31599840).

Open the original third-party study record

Evidence tier: Robust human evidence from peer-reviewed randomized phase 3 clinical trials, limited to the studied indication and population.
Study design: Two identical multicenter, randomized, double-blind, placebo-controlled phase 3 parallel-group clinical trials (RECONNECT).
Study population: 1,267 premenopausal women with hypoactive sexual desire disorder were randomized; 1,202 were included in the reported efficacy population. Participants were adults meeting the study’s HSDD criteria.
Study endpoints: Coprimary endpoints were change from baseline to end of study in the Female Sexual Function Index desire-domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13.
Limitations: The evidence is restricted to premenopausal women with the study-defined HSDD population and does not establish findings for other populations, conditions, or purposes. The report was funded by industry sponsors. This study does not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: The cited study concerns a specific clinical-study product and protocol, not an EZpeps research material. Its findings should not be treated as evidence of identity, quality, equivalence, safety, suitability, or use of that material.

Additional third-party sources

Open research source 1
PubMed / National Library of Medicine (record for Annals of the New York Academy of Sciences) PubMed-indexed clinical-trial publication
Open research source 2
PubMed / National Library of Medicine (record for International Journal of Impotence Research) PubMed-indexed Phase I randomized controlled clinical trial
Open research source 3
PubMed / National Library of Medicine (record for Obstetrics & Gynecology) PubMed-indexed Phase III randomized controlled clinical-trial publication
Open research source 4
ClinicalTrials.gov / U.S. National Library of Medicine ClinicalTrials.gov registered interventional study record

Listed product

MELANOTAN II

Selected third-party study records

Evidence tier: limited and older human evidence, supplemented by a registered study without posted results. The available records are study-specific and do not establish broad conclusions.

Study record 1 — design, population and limitations

PubMed study record (PMID: 8637402).

Open the original third-party study record

Evidence tier: Limited older primary human evidence
Study design: Single-blind, alternating-treatment, placebo-controlled pilot Phase I clinical trial.
Study population: Three adult healthy male volunteers.
Study endpoints: Pigmentation assessed by quantitative reflectance and visual perception; monitored clinical symptoms and observed erectile responses.
Limitations: Very small pilot sample, older study, short study period, and narrow population limit generalizability; findings are specific to the study material and protocol. This study is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT07437560).

Open the original third-party study record

Evidence tier: Registered Phase 2 study; no posted results
Study design: Recruiting randomized, double-blind, placebo-controlled, parallel-assignment Phase 2 interventional study.
Study population: Estimated 60 adults with stable nonsegmental vitiligo; not healthy volunteers.
Study endpoints: Primary: change from baseline in total Vitiligo Area Scoring Index (VASI). Secondary: VASI50, time to first clinically detectable repigmentation, objective pigmentation by melanin index, Dermatology Life Quality Index, and adverse-event and dermatologic-change measures.
Limitations: ClinicalTrials.gov registration describes planned methods and outcome measures but does not establish an outcome because no results are posted. Estimated enrollment and protocol-specific endpoints may change; the record is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: Melanotan II is not established here as equivalent to afamelanotide, bremelanotide, or any approved product or formulation. The cited study materials and registry record are not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material; the material is not represented for human or animal use.

Additional third-party sources

Open research source 1
PubMed / National Library of Medicine; Life Sciences PubMed-indexed Phase I clinical trial
Open research source 2
PubMed / National Library of Medicine; International Journal of Impotence Research (Nature) PubMed-indexed controlled clinical trial / human study
Open research source 3
PubMed / National Library of Medicine; International Journal of Dermatology (Wiley) PubMed-indexed peer-reviewed review

Listed product

SS-31 – Elamipretide

Selected third-party study records

Elamipretide has peer-reviewed human clinical-trial evidence in primary mitochondrial myopathy, including a phase 3 randomized trial and a smaller randomized crossover trial. The records concern study-specific investigational material and do not establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

Peer-reviewed full-text study record (PubMed Central).

Open the original third-party study record

Evidence tier: Peer-reviewed phase 3 randomized clinical trial; high-tier human evidence for the studied population and study material.
Study design: Multicenter, randomized, double-blind, placebo-controlled, phase 3 parallel-group clinical trial.
Study population: 218 adults with genetically confirmed primary mitochondrial myopathy, enrolled across multiple clinical sites.
Study endpoints: Prespecified primary endpoints were change in six-minute walk test distance and change in the Primary Mitochondrial Myopathy Symptom Assessment total-fatigue score; the protocol also specified additional patient-reported and functional outcomes.
Limitations: Disease-, eligibility-, protocol-, and study-material-specific population; findings cannot be generalized to other populations or to an EZpeps research material. A clinical trial record does not establish product identity, quality, equivalence, safety, suitability, or use outside the study.

Study record 2 — design, population and limitations

Peer-reviewed full-text study record (PubMed Central).

Open the original third-party study record

Evidence tier: Peer-reviewed randomized double-blind placebo-controlled crossover human trial; preliminary, lower-certainty evidence than the phase 3 trial.
Study design: Randomized, double-blind, placebo-controlled, two-period crossover trial (MMPOWER-2).
Study population: 30 participants with genetically confirmed primary mitochondrial myopathy; participants had previously participated in the MMPOWER study, and enrollment was limited by the available eligible cohort.
Study endpoints: The stated primary endpoint was distance walked on the six-minute walk test. Other stated outcomes included patient-reported fatigue and muscle-complaint measures, functional assessments, physical-activity measures, global assessments, and safety assessments.
Limitations: Small, selected cohort; crossover design; short study periods; and no formal sample-size calculation because enrollment was constrained by the prior-study cohort. Its results are not evidence of identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: These records describe research in defined clinical populations and study-specific elamipretide material. They do not establish that an EZpeps research material is the same identity, quality, formulation, or equivalent material, and they do not establish its safety, suitability, or use. The cited studies are not evidence for any research-material recommendation. No registry-only record is relied on here; in general, a registry without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
PubMed / Neurology (American Academy of Neurology) PubMed-indexed randomized clinical trial (phase 3)
Open research source 2
PubMed / Journal of Cachexia, Sarcopenia and Muscle (Wiley) PubMed-indexed randomized controlled trial
Open research source 3
PubMed / Circulation: Heart Failure (American Heart Association) PubMed-indexed randomized controlled trial
Open research source 4
ClinicalTrials.gov (U.S. National Library of Medicine / NIH) ClinicalTrials.gov interventional study record (phase 3)

Listed product

TIRZEPATIDE

Selected third-party study records

Evidence tier: robust human evidence from a large peer-reviewed phase 3 randomized trial in a defined population. The study concerns its investigated clinical product and protocol; it does not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 35658024).

Open the original third-party study record

Evidence tier: Robust human evidence: peer-reviewed phase 3 randomized controlled trial.
Study design: Phase 3, randomized, double-blind, placebo-controlled, parallel-group clinical trial.
Study population: A total of 2,539 adults with obesity, or overweight with at least one weight-related complication, and without diabetes; adults had a body-mass index of at least 30, or at least 27 with a qualifying complication.
Study endpoints: Coprimary endpoints were percentage change in body weight from baseline and the proportion with body-weight reduction of 5% or more. The study also specified cardiometabolic measures and safety outcomes.
Limitations: Population and findings are specific to the trial eligibility criteria, studied product, comparator, protocol, and prespecified assessment period; they do not establish conclusions for other materials or formulations. The study was sponsored by Eli Lilly, and longer-term or broader-population evidence is not established by this record.

Study-record limitation: This entry reports study design and named outcome measures, not outcome effects or use guidance. A registry record without posted results does not establish an outcome. Any cited study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
New England Journal of Medicine (indexed in PubMed) PubMed-indexed primary randomized clinical trial report (SURMOUNT-1)
Open research source 2
New England Journal of Medicine (indexed in PubMed) PubMed-indexed primary randomized clinical trial report (SURPASS-2)
Open research source 3
ClinicalTrials.gov, U.S. National Library of Medicine / National Institutes of Health ClinicalTrials.gov registered interventional study record

Listed product

MOTS-c

Selected third-party study records

MOTS-c evidence includes a small observational human study of endogenous circulating levels and a registered interventional study of native MOTS-c. The human observational record did not administer MOTS-c; the registry record has no posted results.

Study record 1 — design, population and limitations

PubMed study record (PMID: 41551324).

Open the original third-party study record

Evidence tier: Limited observational human evidence; not an intervention study.
Study design: Peer-reviewed observational study with cross-sectional comparisons and a longitudinal observational subgroup analysis; also included adipose-tissue immunofluorescence assessment.
Study population: Adults comprising 22 lean controls and 32 adults with obesity scheduled for bariatric surgery; longitudinal data were available for 10 of the adults with obesity, and adipose-tissue assessments included 6 lean kidney donors and 14 adults with obesity.
Study endpoints: Prespecified or stated study measures included circulating MOTS-c levels; metabolic parameters including BMI and HOMA-IR; inflammatory markers; longitudinal weight and circulating MOTS-c measurements; and adipose-tissue MOTS-c expression.
Limitations: MOTS-c was measured rather than administered, so this study cannot establish clinical treatment effects or safety. The sample was small, the cohorts were specialized, and the longitudinal subgroup was smaller than the cross-sectional sample. The study is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT07505745).

Open the original third-party study record

Evidence tier: Registered human interventional study; recruiting with no posted results.
Study design: Phase 2a randomized, double-blind, placebo-controlled, parallel-group interventional study; estimated enrollment is 120 participants.
Study population: Adults aged 18 to 65 with prediabetes and overweight or obesity; the record lists BMI eligibility of 27.0 to 40.0 kg/m² and excludes established diabetes, among other criteria.
Study endpoints: Primary outcome measures are change from baseline in OGTT-derived insulin sensitivity (Matsuda Index) and incidence of treatment-emergent adverse events. Secondary measures include change from baseline in HbA1c, fasting glucose, 2-hour plasma glucose during OGTT, and immunogenicity if applicable.
Limitations: This is a registry protocol, not a results report; no results are posted, and registration does not establish an outcome. The record concerns a specific investigational study product and protocol, not an EZpeps material. It is not evidence of identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: MOTS-c evidence remains limited and study-specific. The observational human study measured endogenous MOTS-c and cannot establish intervention effects. The ClinicalTrials.gov record documents a recruiting study but has no posted results; a registry without posted results does not establish an outcome. Any cited study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
Elsevier (Cell Metabolism) PubMed-indexed primary research article
Open research source 2
Wiley (Physiological Reports) PubMed-indexed primary research article
Open research source 3
Frontiers Media SA (Frontiers in Endocrinology) PubMed-indexed review article

Listed product

BPC-157 + TB-500 aka Wolverine (50/50)

Selected third-party study records

Evidence tier: No authoritative human study of the BPC-157 plus TB-500 combination was identified. The records below are component-specific: one small human BPC-157 pilot and one registered human study of recombinant thymosin beta-4. Component or registry evidence is not evidence for the blend.

Study record 1 — design, population and limitations

PubMed study record (PMID: 40131143).

Open the original third-party study record

Evidence tier: Limited human component evidence; preliminary pilot study, not evidence for the BPC-157 plus TB-500 blend.
Study design: IRB-approved, single-site pilot study with pre/post clinical laboratory and vital-sign assessments and participant questioning about side effects; no comparator group.
Study population: Two adults at a private clinic in Florida: a 58-year-old Asian man and a 68-year-old Caucasian woman; both had prior BPC-157 exposure as described in the PubMed record.
Study endpoints: Study assessments included blood biomarkers relating to heart, liver, kidney, thyroid, and glucose; vital signs; and participant-reported side effects.
Limitations: Only two participants, no control group, prior participant exposure, and limited follow-up and outcome scope. It studied BPC-157 alone, not TB-500 or the combination, and cannot establish evidence for the blend.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT04555824).

Open the original third-party study record

Evidence tier: Registered human component evidence without posted results; recombinant thymosin beta-4 registry evidence is not evidence for TB-500 identity or for the blend.
Study design: Randomized, double-blind, placebo-controlled, parallel-assignment, phase 1a interventional study in seven cohorts.
Study population: 54 healthy Chinese adult volunteers, ages 18 to 50, studied in Beijing, China.
Study endpoints: The registered outcome measures included adverse events, pharmacokinetic parameters, and potential immunological reaction assessed by antibody formation.
Limitations: ClinicalTrials.gov displays no posted results, so the registry does not establish an outcome. The study concerned recombinant thymosin beta-4 (NL005), not TB-500 as a commercial or research-material designation, and did not study BPC-157 or the combination.

Study-record limitation: These records do not establish identity, quality, equivalence, safety, suitability, or use of any EZpeps research material. No blend-specific human study was identified; component findings cannot be transferred to the combination. The ClinicalTrials.gov registry record has no posted results and therefore does not establish an outcome.

Additional third-party sources

Open research source 1
PubMed / Springer, Current Reviews in Musculoskeletal Medicine PubMed-indexed peer-reviewed narrative/scoping review
Open research source 2
PubMed / Alternative Therapies in Health and Medicine PubMed-indexed human pilot study
Open research source 3
PubMed / Journal of Cellular and Molecular Medicine (Wiley) PubMed-indexed phase I clinical trial
Open research source 4
ClinicalTrials.gov, U.S. National Library of Medicine / NIH ClinicalTrials.gov study record

Listed product

KLOW (KPV / BPC-157 / TB-500 / GHK-Cu)

Selected third-party study records

No authoritative human study of the four-component KLOW blend (GHK-Cu, BPC-157, TB-500-related thymosin beta-4, and KPV) was identified. The records below are component-specific and must not be generalized to the blend.

Study record 1 — design, population and limitations

PubMed study record (PMID: 40131143).

Open the original third-party study record

Evidence tier: Very limited human component evidence; not evidence for KLOW.
Study design: IRB-approved, two-participant pilot study with baseline and follow-up clinical measurements; no comparator and no randomization reported.
Study population: Two adults, one 58-year-old man and one 68-year-old woman, both reported as having prior exposure to BPC-157; conducted at a private clinic in Florida.
Study endpoints: Study objective and measured outcomes included vital signs, blood tests covering heart, liver, kidney, thyroid, and blood-glucose biomarkers, and participant-reported side effects.
Limitations: Very small uncontrolled pilot, prior participant exposure, private-clinic setting, and limited follow-up. It studied BPC-157 alone rather than KLOW, GHK-Cu, TB-500, or KPV, so it does not establish evidence for the blend or its other components.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT04555824).

Open the original third-party study record

Evidence tier: Registered human component study with no posted results; not evidence for KLOW or TB-500 identity.
Study design: Completed randomized, double-blind, placebo-controlled, parallel-assignment phase 1 interventional study; actual enrollment 54.
Study population: Healthy Chinese volunteers aged 18 to 50 years; all sexes eligible.
Study endpoints: Prespecified outcome measures included treatment-related adverse events assessed with CTCAE v4.03 and potential immunological reaction measured by antibody formation.
Limitations: The registry has no posted results, so registration does not establish any outcome. The study concerned a specified recombinant thymosin-beta-4 study product, not TB-500 or the KLOW blend; identity, quality, equivalence, or applicability to an EZpeps research material is not established.

Study-record limitation: These component records are not evidence of KLOW blend identity, quality, equivalence, safety, suitability, or use. No controlled human study of the KLOW combination was identified in the reviewed authoritative sources. Registry information without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
PubMed / Current Reviews in Musculoskeletal Medicine (Springer) PubMed-indexed peer-reviewed narrative/scoping review
Open research source 2
ClinicalTrials.gov, U.S. National Library of Medicine / NIH ClinicalTrials.gov interventional study record (completed)
Open research source 3
ClinicalTrials.gov, U.S. National Library of Medicine / NIH ClinicalTrials.gov phase 1 study record (withdrawn; no participants enrolled)
Open research source 4
PubMed Central / International Journal of Molecular Sciences (MDPI) Peer-reviewed journal review

Listed product

IPA + CJC-1295 No DAC

Selected third-party study records

No published controlled human study of the specific ipamorelin (IPA) plus CJC-1295 No DAC blend was identified in the verified sources. The records below are component or registry evidence only and are not evidence for the blend.

Study record 1 — design, population and limitations

PubMed study record (PMID: 10496658).

Open the original third-party study record

Evidence tier: Limited component-level human evidence for ipamorelin; not evidence for the blend or for CJC-1295 No DAC.
Study design: Human clinical PK/PD trial in multiple exposure-level cohorts; PubMed classifies it as a clinical trial and randomized controlled trial.
Study population: Healthy adult male volunteers; eight participants were studied in each of five cohorts (40 participants total).
Study endpoints: Stated purpose and measures were ipamorelin pharmacokinetics and pharmacodynamics, including measured ipamorelin and growth-hormone concentrations and PK/PD model parameters.
Limitations: Studies ipamorelin alone, not the combination; healthy male volunteer population and PK/PD measures do not establish clinical outcomes. It does not identify, validate, or study an EZpeps material, CJC-1295 No DAC, blend composition, identity, quality, equivalence, safety, suitability, or use.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT00267527).

Open the original third-party study record

Evidence tier: Registered human component-level study with no posted results; not evidence for the blend or specifically for CJC-1295 No DAC.
Study design: Terminated, multicenter, randomized, placebo-controlled, double-blind, parallel-assignment Phase 2 interventional study; enrollment listed as 120.
Study population: Adults aged 18–65 with HIV-associated visceral obesity; healthy volunteers were not eligible.
Study endpoints: The registry states study outcome domains of efficacy, pharmacokinetics, safety, and tolerability; no posted results are available.
Limitations: The record names CJC-1295 but does not establish the No-DAC form, and it does not study ipamorelin or the advertised blend. Termination and absence of posted results mean registration does not establish an outcome. It does not identify, validate, or establish identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: These records are component/registry evidence only and must not be read as evidence for the IPA plus CJC-1295 No DAC blend. The specific blend, its composition, identity, quality, equivalence, safety, suitability, and use are not established by these sources. ClinicalTrials.gov registration without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
PubMed / National Library of Medicine; European Journal of Endocrinology PubMed-indexed peer-reviewed original research
Open research source 2
PubMed / National Library of Medicine; The Journal of Clinical Endocrinology & Metabolism PubMed-indexed randomized controlled trial
Open research source 3
PubMed / National Library of Medicine; Growth Hormone & IGF Research PubMed-indexed peer-reviewed original human research
Open research source 4
ClinicalTrials.gov / U.S. National Library of Medicine (NIH) ClinicalTrials.gov interventional study record

Listed product

GLOW combo

Selected third-party study records

Evidence tier: No human study of the GLOW combination itself was identified in the verified sources. The records below are component-specific studies and are not evidence for the blend or for the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 1 — design, population and limitations

PubMed study record (PMID: 16847171).

Open the original third-party study record

Evidence tier: Limited, older human component evidence for GHK-Cu; not evidence for the GLOW blend.
Study design: Randomized controlled study with blinded evaluator assessment and questionnaire-based follow-up.
Study population: Thirteen patients with circumoral CO2 laser-resurfaced skin completed the study; participants were randomized to post-procedure skin-care regimens with or without a copper tripeptide complex.
Study endpoints: Computer- and blinded-evaluator assessments of erythema; assessments of overall wrinkle improvement and overall skin appearance; and a validated questionnaire concerning skin quality.
Limitations: Small, older, single-study component evidence in a specific dermatologic setting. The studied material and context do not establish the composition, identity, quality, equivalence, safety, suitability, or use of the GLOW combination or an EZpeps research material.

Study record 2 — design, population and limitations

PubMed study record (PMID: 40131143).

Open the original third-party study record

Evidence tier: Very limited human pilot evidence for BPC-157; not evidence for the GLOW blend.
Study design: IRB-approved pilot study with within-participant clinical and laboratory assessments.
Study population: Two adults participated: a 58-year-old Asian man and a 68-year-old Caucasian woman; both had prior exposure to the study peptide.
Study endpoints: Blood biomarkers involving the heart, liver, kidneys, thyroid, and blood glucose; vital signs; and participant-reported side effects.
Limitations: Only two participants, private-clinic setting, no comparator, and limited generalizability; the record is not evidence for the GLOW combination. It does not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study-record limitation: No authoritative clinical record verified here studied the GLOW combination as a blend, and the supplied commercial composition or ratio is not established by these sources. Component findings cannot be generalized to the blend or to an EZpeps research material. A registry record without posted results would establish that a study was registered, not an outcome; registry evidence, if located, would likewise not establish the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Additional third-party sources

Open research source 1
PubMed / International Journal of Molecular Sciences PubMed-indexed peer-reviewed review
Open research source 2
PubMed / Cell and Tissue Research (Springer Nature) PubMed-indexed peer-reviewed review
Open research source 3
PubMed / Drug Testing and Analysis (Wiley) PubMed-indexed peer-reviewed analytical research paper

Listed product

GLP-3 (Reta)

Selected third-party study records

Retatrutide (LY3437943) is an investigational triple-receptor agonist studied in human clinical research. The strongest directly verified record is a peer-reviewed phase 2 randomized trial; a separate phase 3 registry record is completed but has no posted results.

Study record 1 — design, population and limitations

PubMed study record (PMID: 37366315).

Open the original third-party study record

Evidence tier: Robust human evidence from one peer-reviewed phase 2 randomized controlled trial; retatrutide remains investigational.
Study design: Phase 2, double-blind, randomized, placebo-controlled clinical trial.
Study population: 338 adults with obesity, or with overweight plus at least one weight-related condition; participants were adults of both sexes.
Study endpoints: Prespecified endpoints included percentage change in body weight, categorical body-weight reduction thresholds, and safety assessment.
Limitations: Evidence comes from one phase 2 trial in a defined adult population and does not establish long-term findings, broader-population applicability, regulatory approval, or equivalence to another formulation. The study was funded by Eli Lilly. The clinical-trial material is not evidence of the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material.

Study record 2 — design, population and limitations

ClinicalTrials.gov study record (NCT05882045).

Open the original third-party study record

Evidence tier: Registered phase 3 human study record; no results posted, so the registry does not establish an outcome.
Study design: Completed, randomized, double-blind, parallel-assignment, placebo-controlled phase 3 interventional study.
Study population: 1,946 enrolled adults with severe obesity and established cardiovascular disease; healthy volunteers were not accepted.
Study endpoints: Stated outcome measures included percent change in body weight; changes in body-mass index, waist circumference, blood pressure, hemoglobin A1c, fasting insulin, physical-function score, and lipid measures; and a pharmacokinetic measure.
Limitations: This is a registry record rather than a posted-results report, and therefore cannot establish efficacy, safety, or any other outcome. Its population is limited to adults with severe obesity and established cardiovascular disease. The registry record does not establish regulatory approval or equivalence to an EZpeps research material; study material is not evidence of the identity, quality, equivalence, safety, suitability, or use of that material.

Study-record limitation: These records concern study-specific retatrutide research and cannot be used to infer the identity, quality, equivalence, safety, suitability, or use of an EZpeps research material. Retatrutide is investigational; registry enrollment or completion without posted results does not establish an outcome.

Additional third-party sources

Open research source 1
National Library of Medicine, PubMed (article published in The New England Journal of Medicine) PubMed-indexed randomized controlled clinical trial (phase 2)
Open research source 2
National Library of Medicine, PubMed (article published in The Lancet) PubMed-indexed randomized controlled clinical trial (phase 2)
Open research source 3
ClinicalTrials.gov, U.S. National Library of Medicine / NIH ClinicalTrials.gov interventional phase 3 study record

General research topics

Reference material not organized as a listed product.

Some external material may discuss a broader research topic or a compound that is not one of the 18 product-organized entries above. It is kept separate from the product library so no source is presented as a record for an EZpeps product.

General-topic material does not indicate that a product is offered, tested, approved, or appropriate for any purpose.
AOD-9604, Tesamorelin, IGF-1 LR3, and Epithalon are not current product-specific entries in the 18-product source library.

FDA source records and external research, properly scoped.

FDA approval history, properly scoped.

Tirzepatide

PT-141

SS-31 – Elamipretide

Gonadorelin

Reference-only research library.

Semaglutide

Selected third-party study records

Original public sources

Tesamorelin

Selected third-party study records

Original public sources

Teduglutide

Selected third-party study records

Original public sources

Cetrorelix

Selected third-party study records

Original public sources

Larazotide

Selected third-party study records

Original public sources

Kisspeptin-54

Selected third-party study records

Original public sources

AOD-9604

Selected third-party study records

Original public sources

Humanin

Selected third-party study records

Original public sources

External research records, organized by listed product.

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Selected third-party study records

Additional third-party sources

Reference material not organized as a listed product.

Optional analytics and advertising measurement